 Aravive, Inc. ARAV, a clinical-stage biopharmaceutical company, announced that AVB-500 improves anti-tumor effects when combined with the anti-angiogenic bevacizumab or the PARP inhibitor olaparib in pre-clinical uterine cancer models. Additional research also showed that inhibition of GAS6AXL signaling with AVB-500 induces BRCA-ness, increasing response to platinum and PARPi in a preclinical model of ovarian cancer. 